Skip to content
OpenCapital
Get started

Olema Pharmaceuticals, Inc. OLMA Q1 2026 earnings

Reported May 12, 2026 · Before market open

Diluted EPS-$0.52In line
EPS estimate-$0.52

Next report

Aug 10, 2026 (In 4 weeks)
EPS estimate-$0.53

Financials

Q1 2026

Income statement

See full
Operating income-$58.0M-66.3%
Net income-$53.1M-74.7%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$52.5M+3.8%
Total debt$956.0K-16.7%
Total equity$480.5M+25.3%
Total assets$530.6M+29.5%

Cash flow

See full
Operating cash flow-$46.0M-4.6%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$1.07B+406%
Enterprise value$1.02B+502%

Returns & leverage

See full
Return on equity-42.9%+1.3pp
Debt / equity0×0.0×
Current ratio10.9×-4.3×

Versus estimates

Diluted EPS

Q1 2026-$0.52In line
Q4 2025-$0.50Beat by $0.01Q3 2025-$0.49Miss by $0.05Q2 2025-$0.51Miss by $0.08Q1 2025-$0.36Beat by $0.13Q4 2024-$0.51Beat by $0.12

Ask the moment Olema Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Olema Pharmaceuticals, Inc. report Q1 2026 earnings?
Olema Pharmaceuticals, Inc. (OLMA) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Olema Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Olema Pharmaceuticals, Inc. reported diluted EPS of $-0.52 for Q1 2026.
Did Olema Pharmaceuticals, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.52 by $0.00.
How did Olema Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 44.4% from $-0.36.
Where can I find Olema Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-218142) and the 10-Q periodic report (0001193125-26-218156) directly on SEC EDGAR. The filing index links above go to sec.gov.